GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 07:03:04 2025-07-08 am EDT			5-day change	1st Jan Change
1,391.00 ^GBX	-0.32%		-1.35%	+3.49%

05:58am	GSK: acquires efimosfermin alfa	CF
Jul. 07	GSK plc completed the acquisition of Efimosfermin alfa drug from Boston Pharmaceuticals Inc.	CI

European Equities Traded in the US as American Depositary Receipts Rise Thursday

Published on 06/12/2025 at 11:19

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about GSK plc

GSK: acquires efimosfermin alfa	05:58am	CF
GSK plc completed the acquisition of Efimosfermin alfa drug from Boston Pharmaceuticals Inc.	Jul. 07	CI
Sector Update: Health Care Stocks Weaker Late Afternoon	Jul. 07	MT
Sector Update: Health Care	Jul. 07	MT
GSK Finalizes Acquisition of Boston Pharmaceuticals' Liver Disease Drug Candidate	Jul. 07	MT
UK's MHRA flags Guillain-Barré syndrome risk post Abrysvo & Arexvy vaccination in adults 60 years & older	Jul. 07	RE
UK stocks stabilise a day after selloff on fiscal concerns	Jul. 03	RE
Pound climbs, bond yields ease as PM backs Reeves	Jul. 03	AN
GSK : UBS reiterates its Neutral rating	Jul. 03	ZD
US CDC accepts ousted vaccine panel's recommendations for RSV, meningococcal shots	Jul. 02	RE
US CDC accepts ousted vaccine panel's recommendations for RSV, meningococcal shots	Jul. 02	RE
AlphaValue/Baader Europe Upgrades GSK to Buy, Trims PT	Jul. 01	MT
GSK : UBS reaffirms its Neutral rating	Jul. 01	ZD
PreveCeutical Medical Inc. Appoints Francis Tavares as Chief Technology Officer, Effective 27 June, 2025	Jun. 30	CI
UK's midcaps record best quarter in more than four years, blue-chip index down	Jun. 30	RE
UK's midcaps record best quarter in more than four years, blue-chip index down	Jun. 30	RE
Moderna says flu shot more effective than rival GSK in late-stage study	Jun. 30	RE
GSK : Gets a Neutral rating from Goldman Sachs	Jun. 30	ZD
US Senator Launches Probe Into GSK's Decision to Pull Children's Inhaler	Jun. 30	MT
Babcock International price targets raised	Jun. 30	AN
GSK : JP Morgan reiterates its Sell rating	Jun. 30	ZD
GSK Spokesperson Details Steps to Promote Inhalers' Accessibility Amid Looming US Investigation	Jun. 29	MT
Gilead shares rise after US top court ruling on preventive coverage	Jun. 27	RE
Sector Update: Health Care Stocks Retreat Late Afternoon	Jun. 27	MT
US senator probes GSK's halt of children's asthma inhaler	Jun. 27	RE

GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

Employees

68,629

Sector

Pharmaceuticals

Calendar

Jul. 30 - Q2 2025 Earnings Release

More about the company